Qvents
Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Home
About Us
Contact Us
Expert Panel
Tags
Qvents
Warning Letters
483s
Recalls
Import Alerts
Quality Insights
Tags
Forums
Learning Resources
Upcoming Trainings
Training Archives
Guidelines
Pharma Jobs
Job Openings
Post a Job
Jobs posted by me
Users & Profiles
News
Login/Register
Individual
Company
Home
About Us
Contact Us
Expert Panel
Tags
Qvents
Warning Letters
483s
Recalls
Import Alerts
Quality Insights
Tags
Forums
Learning Resources
Upcoming Trainings
Training Archives
Guidelines
Pharma Jobs
Job Openings
Post a Job
Jobs posted by me
Users & Profiles
News
Login/Register
GMP Good Manufacturing Practices – Medicinal Products and Active Pharmaceutical Ingredients (APIs)
Qvents
2 minutes read
Uncategorized
Home
Guidelines
GMP Good Manufacturing Practices – Medicinal Products and Active Pharmaceutical Ingredients (APIs)
Updated on January 30, 2025
Home
Guidelines
GMP Good Manufacturing Practices – Medicinal Products and Active Pharmaceutical Ingredients (APIs)
Updated on January 30, 2025
USFDA
21CFR PART 210
—
Current Good Manufacturing Practice in Manufacturing, Processing, Packing, Or Holding Of Drugs; General
USFDA
21 CFR PART 211
—
Current Good Manufacturing Practice For Finished Pharmaceuticals
USFDA:
Q&A on CGMP Requirements
USFDA Q&A:
Questions and Answers on Current Good Manufacturing Practice Requirements – Control of Components and Drug Product Containers and Closures
USFDA
:
Microbiological Quality Considerations in Non-Sterile Drug Manufacturing
USFDA:
FDA advises drug manufacturers that Burkholderia cepacia complex (BCC) poses a contamination risk in non-sterile, water-based drug products
WHO
TRS 986 – Annex 2
:
WHO Good Manufacturing Practices for
Pharmaceutical Products
: Main Principles
WHO
TRS 957 – Annex 2
:
WHO Good Manufacturing Practices fFor Active Pharmaceutical Ingredients (APIs – Bulk Drug Substances)
WHO
TRS 957 – Annex 3
:
WHO good manufacturing practices for pharmaceutical products containing hazardous substances
WHO:
Quality assurance of pharmaceuticals: A compendium of guidelines and related materials; Tenth Edition : Volume 2 Good manufacturing practices and inspection
Europe:
EudraLex – Volume 4 – Good Manufacturing Practice (GMP) guidelines
EudraLex
Introduction
EudraLex –
Part I – Basic Requirements for Medicinal Products
EudraLex –
Part II – Basic Requirements for Active Substances used as Starting Materials
EudraLex –
Part III – GMP related documents
EudraLex –
Annexes
EudraLex –
Guidance On Good Manufacturing Practice and Good Distribution Practice:
Questions And Answers
EudraLex:
Other documents related to GMP and GDP
EMA:
Guideline on manufacture of the finished dosage form
(EMA/CHMP/QWP/245074/2015)
PIC/S:
Guide To Good Manufacturing Practice for Medicinal Products
PIC/S GMP
Guide (
Part I: Basic Requirements for Medicinal Products)
PIC/S GMP
Guide (
Part II: Basic Requirements for Active Pharmaceutical Ingredients
)
PIC/S GMP
Guide To Good Manufacturing Practice for Medicinal Products
ANNEXES
PIC/S:
Remote Assessments
PIC/S: Remote Assessments-
Aide-Memoire
ICH Q7A
: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
ICH Q7A – Q&A
(ICH)
&
Q&A presentation
APIC – GMPs for APIs – How to do
– Interpretation of ICH Q7 Guide
MHRA
(
UK
):
Volume 4 of the rules governing medicinal products in the EU
TGA (Australia):
PE009, the PIC/S guide to GMP for medicinal products
;
TGA interpretation and expectations for demonstrating compliance
Health Canada:
Good manufacturing practices guide for drug products (GUI-0001)
South Africa- SA Guide To Good Manufacturing Practice for Medicines
(SAHPRA);
SAPHRA Guidelines Page
India DCGI / CDSCO
:
Revised Schedule M (Gazette Notification December 2023)
Share:
Facebook
LinkedIn
Twitter
Search Posts
Latest Posts
USFDA 483 Cites Piramal Pharma for Investigation Deficiencies, Procedural Non-Compliance
March 13, 2025
Contamination Control and Data Integrity Issues: Granules India Receives USFDA Warning Letter
March 7, 2025
Janssen’s Korea Vaccine Unit USFDA 483 Cites Aseptic Operations Not in Control
February 26, 2025
Facility Registration Violations, Refusal of Inspection: Jagsonpal Issued Warning letter
February 22, 2025
Purified Water System Qualification and Control: USFDA Expectations
February 11, 2025